Efficacy of intravesical chondroitin sulphate in treatment of interstitial cystitis/bladder pain syndrome (IC/BPS): Individual patient data (IPD) meta-analytical approach
DOI:
https://doi.org/10.5489/cuaj.1257Abstract
Background: Raw data from 3 similar clinical trials were analyzed in this individual participant data (IPD) meta-analysis to define any possible efficacy of intravesical 2% chondroitin sulphate in IC/BPS.
Methods: We pooled IPD from an open label and 2 small randomized placebo controlled trials assessing chondroitin sulphatein IC/BPS (similar inclusion/exclusion criteria, treatment, outcome assessment). Our primary objective was to compare rates of global response assessment (GRA) responsiveness between chondroitin sulphate and vehicle control. Secondary objectives compared the Interstitial Cystitis Symptom/Problem Index (ICSI/PI) total score and improvement rates, and average daily urine frequency. The treatment response was calculated for individual trials and pooled data using IPD meta-analysis for pooling proportions.
Results: In total, 213 patients were included in the pooling analysis. At the end of the treatment period, the overall GRA response rates were 43.2 (95% CI: 35.0, 51.5) and 27.4 (95% CI: 17.6, 37.2) for the chondroitin sulphate and vehicle control groups, respectively. Pooled RR was 1.55 (p = 0.014, 95% CI: 1.09, 2.22). The chance of being an ICSI responder was similarly 54% higher in the chondroitin sulphate group. The small decrease in total ICSI score and urine frequency between the two groups was less impressive (-0.8 and -0.5 points respectively) and not statistically significant.
Conclusions: Benefits from intravesical chondroitin sulphate treatment in IC/BPS patients can be confirmed by increasing the power of the available data using an IPD meta-analytical approach. However, disconnect between response rates and severity scores underline the importance of choosing the right patient for this organ-specific treatment.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.